Akio Murase

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist
    Akio Murase
    Pfizer Global Research and Development, Discovery Biology Research, Aichi, Japan
    Life Sci 82:226-32. 2008
  2. ncbi Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation
    Akio Murase
    Pfizer Global Research and Development, Pfizer Inc, Discovery Biology Research, Nagoya Laboratories, 5 2, Taketoyo, Aichi, 470 2393, Japan
    Eur J Pharmacol 580:116-21. 2008
  3. ncbi Effects of the selective EP4 antagonist, CJ-023,423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis
    Takako Okumura
    Discovery Biology Research, Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Inc, 5 2 Taketoyo, Aichi, 470 2393, Japan
    J Pharm Pharmacol 60:723-30. 2008
  4. ncbi CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties
    Kazunari Nakao
    Discovery Biology Research, Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Inc, 5 2 Taketoyo, Aichi, 470 2393, Japan
    J Pharmacol Exp Ther 322:686-94. 2007
  5. ncbi Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship
    Shigeo Hayashi
    Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Japan Inc, 5 2 Taketoyo, Aichi 470 2393, Japan
    Biochem Pharmacol 82:755-68. 2011
  6. ncbi Characterization of binding affinity of CJ-023,423 for human prostanoid EP4 receptor
    Akio Murase
    Discovery Biology Research, Pfizer Global Research and Development, Aichi, Japan
    Pharmacology 82:10-4. 2008
  7. ncbi Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor
    Takako Okumura
    Discovery Biology Research, Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Inc, 5 2 Taketoyo, Aichi, 470 2393, Japan
    Eur J Pharmacol 539:125-30. 2006

Collaborators

Detail Information

Publications7

  1. ncbi In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist
    Akio Murase
    Pfizer Global Research and Development, Discovery Biology Research, Aichi, Japan
    Life Sci 82:226-32. 2008
    ..These results suggest that CJ-042794, a novel, potent, and selective EP(4) receptor antagonist, has excellent pharmacological properties that make it a useful tool for exploring the physiological role of EP(4) receptors...
  2. ncbi Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation
    Akio Murase
    Pfizer Global Research and Development, Pfizer Inc, Discovery Biology Research, Nagoya Laboratories, 5 2, Taketoyo, Aichi, 470 2393, Japan
    Eur J Pharmacol 580:116-21. 2008
    ..These results suggest that a pharmacological blockade of the prostanoid EP(4) receptor may represent a new therapeutic strategy in signs and symptomatic relief of osteoarthritis and/or rheumatoid arthritis...
  3. ncbi Effects of the selective EP4 antagonist, CJ-023,423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis
    Takako Okumura
    Discovery Biology Research, Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Inc, 5 2 Taketoyo, Aichi, 470 2393, Japan
    J Pharm Pharmacol 60:723-30. 2008
    ..This is the first study to confirm the in-vivo effects of EP4 receptor blockade on inflammation and bone destruction in AIA rats with a small-molecule compound...
  4. ncbi CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties
    Kazunari Nakao
    Discovery Biology Research, Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Inc, 5 2 Taketoyo, Aichi, 470 2393, Japan
    J Pharmacol Exp Ther 322:686-94. 2007
    ..Thus, specific blockade of the EP(4) receptor signaling may represent a novel therapeutic approach for the treatment of inflammatory pain...
  5. ncbi Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship
    Shigeo Hayashi
    Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Japan Inc, 5 2 Taketoyo, Aichi 470 2393, Japan
    Biochem Pharmacol 82:755-68. 2011
    ..These results suggest that compounds 1-3 are potential agents for the treatment of inflammatory disease and are useful for further pharmacological COX-2 inhibitor investigations...
  6. ncbi Characterization of binding affinity of CJ-023,423 for human prostanoid EP4 receptor
    Akio Murase
    Discovery Biology Research, Pfizer Global Research and Development, Aichi, Japan
    Pharmacology 82:10-4. 2008
    ..4) and isotonic buffer conditions. In this report, the binding mechanism between CJ-023,423 and human EP4 receptor is discussed based on the binding affinities determined under various assay conditions...
  7. ncbi Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor
    Takako Okumura
    Discovery Biology Research, Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Inc, 5 2 Taketoyo, Aichi, 470 2393, Japan
    Eur J Pharmacol 539:125-30. 2006
    ....